EUCTR2017-002773-19-GB进行中（未招募）1 期
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Ibrutinib in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 78
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Male or female, 18 years or older.
- •Histologically documented diagnosis of DLBCL.
- •- For Phase 1, subjects may have any DLBCL subtype.
- •- For Phase 2, subjects must have ABC or unclassifiable subtypes of DLBCL confirmed by immunohistochemistry using the Hans algorithm.
- •Relapsed or refractory DLBCL, defined as having received at least 1 but no more than 3 prior treatment regimens and ineligible for high-dose chemotherapy/autologous stem cell transplant.
- •Fluorodeoxyglucose-avid disease (based on local evaluation) per the Lugano Classification. Fluorodeoxyglucose-avid disease is defined as disease with a 5-point scale score of 4 or 5.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 18
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 42
排除标准
- •Transformed DLBCL or DLBCL with coexistent histologies (eg, follicular or mucosa-associated lymphoid tissue lymphoma).
- •Primary mediastinal (thymic) large B-cell lymphoma.
- •Known central nervous system lymphoma (either primary or metastatic).
- •Autologous stem cell transplant within the previous 3 months, allogeneic stem cell transplant within the previous 6 months, or active graft versus host disease following allogeneic transplant.
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the impact of Itacitinib when added to Ibrutinib for the treatment of relapsed or refractory diffuse large B-Cell lymphomaEUCTR2017-002773-19-ITINCYTE CORPORATIO78
进行中（未招募）
1 期
A study evaluating the impact of Itacitinib when added to Ibrutinib for the treatment of relapsed or refractory diffuse large B-Cell lymphomaRelapsed or refractory diffuse large B-cell lymphomaMedDRA version: 20.0Level: PTClassification code 10012822Term: Diffuse large B-cell lymphoma refractorySystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10012821Term: Diffuse large B-cell lymphoma recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-002773-19-BEIncyte Corporation78
进行中（未招募）
1 期
A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple MyelomaRelapsed or Refractory Multiple myelomaMedDRA version: 20.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2018-004076-35-ESIncyte Corporation98
进行中（未招募）
1 期
A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia (AIHA)EUCTR2017-003652-22-FRIncyte Corporation20
进行中（未招募）
1 期
A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia (AIHA)EUCTR2017-003652-22-ATIncyte Coorporation25